+1 (202) 780-3397
Editorial - Journal of Cancer Immunology & Therapy (2018) Volume 1, Issue 1
Epigenetic altering drugs as immunotherapies.
Despite of our increasing understanding of the molecular, genetic and phenotypic progression of cancers, treatments that can effectively combat most malignant cancers remain suboptimal [1]. A major challenge with current therapies is that they focus on existing genetic abnormalities but usually become ineffectual due to cancers becoming resistant or not expressing the specific mutation. Advances in high-throughput DNA sequencing of various cancers before and after treatment and after recurrence, has provided researchers with comprehensive collections of driver and passenger mutations that can be utilised to develop novel therapies. However, these sequencing techniques can be costly and usually results in the output of large and complex datasets that require specialised knowledge of different computational analysis [2].
Author(s): Rasika M. Samarasinghe